← Back to Screener
PLUS THERAPEUTICS, Inc. Common Stock (PSTV)
Price$7.30
Favorite Metrics
Price vs S&P 500 (26W)-72.09%
Price vs S&P 500 (4W)-6.43%
Market Capitalization$43.85M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)19.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)187.22%
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-54.26%
Gross Margin (TTM)74.77%
Net Profit Margin (TTM)-429.43%
EPS (TTM)$-1.25
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$-1.25
Revenue Growth (5Y)77.01%
EPS (Annual)$-0.29
ROI (Annual)-471.68%
Gross Margin (Annual)64.36%
Net Profit Margin (5Y Avg)-2577.63%
Cash / Share (Quarterly)$0.06
Revenue Growth QoQ (YoY)-3.19%
ROA (Last FY)-137.13%
Revenue Growth TTM (YoY)-10.49%
EBITD / Share (TTM)$-0.13
ROE (5Y Avg)-441.80%
Operating Margin (TTM)-293.46%
Cash Flow / Share (Annual)$-0.15
P/B Ratio10.97x
P/B Ratio (Quarterly)17.62x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)7.74x
Net Interest Coverage (TTM)-2.66x
ROA (TTM)-156.00%
EPS Incl Extra (Annual)$-0.29
Current Ratio (Annual)1.23x
Quick Ratio (Quarterly)1.12x
3-Month Avg Trading Volume0.41M
52-Week Price Return-61.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)8.41x
Asset Turnover (Annual)0.32x
52-Week High$30.50
Operating Margin (5Y Avg)-2593.87%
EPS Excl Extra (Annual)$-0.29
CapEx CAGR (5Y)-32.83%
Tangible BV CAGR (5Y)7.60%
26-Week Price Return-63.34%
Quick Ratio (Annual)1.12x
13-Week Price Return-11.98%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)1.23x
Enterprise Value$40.342
Revenue / Share Growth (5Y)-41.76%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-83.84%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.44x
Pretax Margin (Annual)-429.43%
Cash / Share (Annual)$0.06
3-Month Return Std Dev139.07%
Gross Margin (5Y Avg)66.98%
Net Income / Employee (TTM)$-1
ROE (Last FY)-560.21%
Net Interest Coverage (Annual)-0.48x
EPS Basic Excl Extra (Annual)$-0.29
P/FCF (TTM)45.20x
Receivables Turnover (TTM)0.53x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-1.25
Receivables Turnover (Annual)0.51x
ROI (TTM)-116.53%
P/S Ratio (TTM)8.41x
Pretax Margin (5Y Avg)-2577.63%
Revenue / Share (Annual)$0.07
Tangible BV / Share (Annual)$0.03
Price vs S&P 500 (52W)-97.04%
Year-to-Date Return-50.12%
5-Day Price Return18.11%
EPS Normalized (Annual)$-0.29
ROA (5Y Avg)-119.13%
Net Profit Margin (Annual)-429.43%
Month-to-Date Return57.39%
Cash Flow / Share (TTM)$-5.64
EBITD / Share (Annual)$-0.20
Operating Margin (Annual)-293.46%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-179.16%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.25
P/TBV (Quarterly)19.22x
P/B Ratio (Annual)17.62x
Inventory Turnover (TTM)0.74x
Pretax Margin (TTM)-429.43%
Book Value / Share (Annual)$0.03
Price vs S&P 500 (13W)-14.85%
Beta1.46x
Revenue / Share (TTM)$0.04
ROE (TTM)-123.76%
52-Week Low$2.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.09
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PSTVPLUS THERAPEUTICS, Inc. Common Stock | 8.41x | 77.01% | 74.77% | -293.46% | $7.30 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Plus Therapeutics is a clinical-stage pharmaceutical company developing treatments for CNS cancers, including recurrent glioblastoma and leptomeningeal metastases. Its lead candidate, rhenium-186 obisbemeda, is a targeted radiotherapeutic designed for cancers with limited treatment options, including pediatric brain cancers.